Lifshitz & Miller LLP Announces Investigation of Akari Therapeutics, Plc, Alexion Pharmaceuticals, Inc., Amgen Inc., Cel-Sci Corp., Dick's Sporting Goods, Inc., Eco Science Solutions, Inc.

NEW YORK, May 30, 2017 /PRNewswire/ --

Akari Therapeutics, Plc (AKTX)

Lifshitz & Miller announces investigation on behalf of AKTX investors concerning whether AKTX issued false information about AKTX's Phase 2 PNH trial of Coversin.

If you are an AKTX investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

Alexion Pharmaceuticals, Inc. (ALXN)

Lifshitz & Miller announces investigation on behalf of ALXN investors concerning whether ALXN was involved in a scheme to subsidize lawsuits for patients to get access to its drug via Brazil's national health system.

If you are an ALXN investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

Amgen Inc. (AMGN)

Lifshitz & Miller announces investigation on behalf of AMGN investors after AMGN disclosed that trials of Evenity, AMGN's osteoporosis medicine, raised heart safety concerns leading to a delay in securing approval of the drug.

If you are an AMGN investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

Cel-Sci Corp. (CVM)

Lifshitz & Miller announces investigation on behalf of CVM investors concerning the reported loss of $8.4 million for the 2017 fiscal second quarter.

If you are a CVM investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

Dick's Sporting Goods, Inc. (DKS)

Lifshitz & Miller announces investigation on behalf of DKS investors after DKS purportedly claimed a computation error resulted in a $23.4 million overstatement of Adjusted EBITDA amounts.

If you are a DKS investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

Eco Science Solutions, Inc. (ESSI)

Lifshitz & Miller announces investigation on behalf of ESSI investors concerning the SEC's suspension of trading in ESSI's securities on May 19, 2017.

If you are an ESSI investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

Intra-Cellular Therapies, Inc. (ITCI)

Lifshitz & Miller announces investigation on behalf of ITCI investors concerning whether ITCI issued misleading statements about the efficacy and safety of ITI-007 for the treatment of schizophrenia.

If you are an ITCI investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

Twilio Inc. (TWLO)

Lifshitz & Miller announces investigation on behalf of TWLO investors after TWLO reduced its 2017 guidance on May 2, 2017.

If you are a TWLO investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

ATTORNEY ADVERTISING.© 2017 Lifshitz & Miller LLP.  The law firm responsible for this advertisement is Lifshitz & Miller LLP, 821 Franklin Avenue, Suite 209, Garden City, New York 11530, Tel: (516)493-9780.  Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact:
Joshua M. Lifshitz, Esq.
Lifshitz & Miller LLP
Phone:  516-493-9780 
Facsimile: 516-280-7376
Email: info@jlclasslaw.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/lifshitz--miller-llp-announces-investigation-of-akari-therapeutics-plc-alexion-pharmaceuticals-inc-amgen-inc-cel-sci-corp-dicks-sporting-goods-inc-eco-science-solutions-inc-intra-cellular-therapies-inc-and-twili-300465549.html

SOURCE Lifshitz & Miller Law Firm